Treatment Approach for Elevated AFP in Testicular Cancer

Critical Diagnostic Principles

• The National Comprehensive Cancer Network (NCCN) recommends that any elevation of AFP above the normal range in a patient with testicular cancer indicates an undetected focus of nonseminomatous elements, and the patient must be managed as having nonseminomatous disease 1, 2, 3
• The NCCN explicitly states that if AFP is positive, the patient should be treated as having nonseminoma 1, 2

Initial Workup Requirements

• Tumor markers, including AFP, β-HCG, and LDH, should be repeated to establish a baseline and confirm elevation 1, 2, 3
• An abdominopelvic CT scan should be performed to assess retroperitoneal nodes, and a chest CT should be done if retroperitoneal adenopathy is present or if the chest x-ray is abnormal 4

Treatment Algorithm Based on Clinical Stage

• For stage I disease with elevated AFP, primary treatment should be radical inguinal orchiectomy followed by chemotherapy 1, 2
• The BEP (Bleomycin/Etoposide/Cisplatin) regimen for 3 cycles is a Category 1 recommendation for stage I, IIA, and IIB disease 1
• For good prognosis nonseminoma, BEP for 3 cycles is recommended, while for intermediate/poor prognosis, BEP for 4 cycles is recommended 1, 2

Monitoring During Treatment

• AFP half-life is 5-7 days, and effective therapy should result in an appropriate decline in AFP levels 1, 2, 3
• Tumor markers, including AFP, β-HCG, and LDH, should be measured before each chemotherapy cycle 3

Post-Chemotherapy Management

• After completing chemotherapy, patients should be assessed for residual masses, and surgical resection should be performed if the residual mass is greater than 3 cm 1

Follow-Up After Treatment

• Follow-up after treatment should include regular monitoring of AFP, β-HCG, and LDH, as well as imaging studies, with the frequency of follow-up decreasing over time 1